ARTICLE | Clinical News
Pfizer planning Phase III for DMD gene therapy, close on Sarepta's heels
June 28, 2019 10:53 PM UTC
Undeterred by two patient hospitalizations revealed in Phase Ib data Friday for its DMD gene therapy, Pfizer is moving forward with plans for a Phase III trial start in 1H20, setting up a tight race to the finish line between it and Sarepta.
Pfizer Inc. (NYSE:PFE) said at the Parent Project Muscular Dystrophy (PPMD) Connect meeting in Orlando its Duchenne muscular dystrophy (DMD) gene therapy PF-06939926 resulted in two hospitalizations among six patients treated...
BCIQ Target Profiles